← All peptides
warningBioGate · AMBERGrade B

Semaglutide

HXEGTFTSDVSSYLEGQAAKEFIAWLVRGRG

GLP-1 receptor agonist with extended half-life (~7 days); stimulates glucose-dependent insulin secretion and central appetite suppression.

AEEA-AEEA-γGlu-C18 lipid sidechain @ K20Aib substitution @ position 2
MW
4113.58
Length
31aa
Posterior
29.7%
Loading Mol* bundle…
PDA-V1 attestation

Cryptographic chain of custody.

Outer PDA hash
Inputs hash
Merkle root
TEE attestation
Protocol version
PDA-V1
Source
peptide-md
Model version
structure-fm-2026.04
Candidates emitted
3
Signed
2026-04-21T08:14:33Z
Verifiable in your browser at /verifier with @peptide-md/verifier.
Verify this attestation →Download dossier (PDF)Compare with…
Real-world evidence

Cohort-attested outcomes.

Cohorts
5
Participants
407
Mean Δ
+6.83
Δ HRV ms (8-week) · 95% CI [6.09, 7.58]
IPNFT · Molecule IPNFT V2Solana
Semaglutide
4c0306…134702
Royalty cascade
13.88%
Holders
18
Royalty cascade routes lab fees, licensing, and OEA-attested cohort revenues back to holders, the cohort treasury, and the originating researchers in a 60 / 25 / 15 split.
Used in protocols

Where this peptide shows up.

Metabolic Reset - GLP-1 Anchored

Grade A

Type 2 diabetes adjunct + obesity (BMI ≥ 30 or BMI ≥ 27 with comorbidity)

Citations

Source literature.

Grade A2021 · N Engl J Med

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)

Wilding JPH et al.

DOI 10.1056/NEJMoa2032183